Quality of life in low-grade glioma patients receiving temozolomide

Raymond Liu, Karla Solheim, Mei-Yin Polley, Kathleen R. Lamborn, Margaretta Page, Anne Fedoroff, Jane Rabbitt, Nicholas Butowski, Michael Prados, Susan M. Chang

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The purpose of this study was to describe the quality of life (QOL) of low-grade glioma (LGG) patients at baseline prior to chemotherapy and through 12 cycles of temozolomide (TMZ) chemotherapy. Patients with his- tologically confirmed LGG with only prior surgery were given TMZ for 12 cycles. QOL assessments by the Functional Assessment of Cancer Therapy-Brain (FACT-Br) were obtained at baseline prior to chemotherapy and at 2-month intervals while receiving TMZ. Patients with LGG at baseline prior to chemotherapy had higher reported social well-being scores (mean difference = 5.0; p < 0.01) but had lower reported emotional well-being scores (mean difference = 2.2; p &t 0.01) compared to a normal population. Compared to patients with left hemisphere tumors, patients with right hemisphere tumors reported higher physical well-being scores (p = 0.01): 44% could not drive, 26% did not feel independent, and 26% were afraid of having a seizure. Difficulty with work was noted in 24%. Mean change scores at each chemotherapy cycle compared to baseline for all QOL subscales showed either no significant change or were significantly positive (p < 0.01). Patients with LGG on TMZ at baseline prior to chemotherapy reported QOL comparable to a normal population with the exception of social and emotional well-being, and those with right hemisphere tumors reported higher physical well-being scores compared to those with left hemisphere tumors. While remaining on therapy, LGG patients were able to maintain their QOL in all realms. LGG patients' QOL may be further improved by addressing their emotional well-being and their loss of independence in terms of driving or working.

Original languageEnglish (US)
Pages (from-to)59-68
Number of pages10
JournalNeuro-Oncology
Volume11
Issue number1
DOIs
StatePublished - Feb 1 2009
Externally publishedYes

Fingerprint

temozolomide
Glioma
Quality of Life
Drug Therapy
Neoplasms
Patient Rights
Brain Neoplasms
Population
Seizures

Keywords

  • Brain tumor, chemotherapy
  • Low-grade glioma
  • Quality of life
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Liu, R., Solheim, K., Polley, M-Y., Lamborn, K. R., Page, M., Fedoroff, A., ... Chang, S. M. (2009). Quality of life in low-grade glioma patients receiving temozolomide. Neuro-Oncology, 11(1), 59-68. https://doi.org/10.1215/15228517-2008-063

Quality of life in low-grade glioma patients receiving temozolomide. / Liu, Raymond; Solheim, Karla; Polley, Mei-Yin; Lamborn, Kathleen R.; Page, Margaretta; Fedoroff, Anne; Rabbitt, Jane; Butowski, Nicholas; Prados, Michael; Chang, Susan M.

In: Neuro-Oncology, Vol. 11, No. 1, 01.02.2009, p. 59-68.

Research output: Contribution to journalArticle

Liu, R, Solheim, K, Polley, M-Y, Lamborn, KR, Page, M, Fedoroff, A, Rabbitt, J, Butowski, N, Prados, M & Chang, SM 2009, 'Quality of life in low-grade glioma patients receiving temozolomide', Neuro-Oncology, vol. 11, no. 1, pp. 59-68. https://doi.org/10.1215/15228517-2008-063
Liu, Raymond ; Solheim, Karla ; Polley, Mei-Yin ; Lamborn, Kathleen R. ; Page, Margaretta ; Fedoroff, Anne ; Rabbitt, Jane ; Butowski, Nicholas ; Prados, Michael ; Chang, Susan M. / Quality of life in low-grade glioma patients receiving temozolomide. In: Neuro-Oncology. 2009 ; Vol. 11, No. 1. pp. 59-68.
@article{f99af58fc9a14206aae0930722877e83,
title = "Quality of life in low-grade glioma patients receiving temozolomide",
abstract = "The purpose of this study was to describe the quality of life (QOL) of low-grade glioma (LGG) patients at baseline prior to chemotherapy and through 12 cycles of temozolomide (TMZ) chemotherapy. Patients with his- tologically confirmed LGG with only prior surgery were given TMZ for 12 cycles. QOL assessments by the Functional Assessment of Cancer Therapy-Brain (FACT-Br) were obtained at baseline prior to chemotherapy and at 2-month intervals while receiving TMZ. Patients with LGG at baseline prior to chemotherapy had higher reported social well-being scores (mean difference = 5.0; p < 0.01) but had lower reported emotional well-being scores (mean difference = 2.2; p &t 0.01) compared to a normal population. Compared to patients with left hemisphere tumors, patients with right hemisphere tumors reported higher physical well-being scores (p = 0.01): 44{\%} could not drive, 26{\%} did not feel independent, and 26{\%} were afraid of having a seizure. Difficulty with work was noted in 24{\%}. Mean change scores at each chemotherapy cycle compared to baseline for all QOL subscales showed either no significant change or were significantly positive (p < 0.01). Patients with LGG on TMZ at baseline prior to chemotherapy reported QOL comparable to a normal population with the exception of social and emotional well-being, and those with right hemisphere tumors reported higher physical well-being scores compared to those with left hemisphere tumors. While remaining on therapy, LGG patients were able to maintain their QOL in all realms. LGG patients' QOL may be further improved by addressing their emotional well-being and their loss of independence in terms of driving or working.",
keywords = "Brain tumor, chemotherapy, Low-grade glioma, Quality of life, Temozolomide",
author = "Raymond Liu and Karla Solheim and Mei-Yin Polley and Lamborn, {Kathleen R.} and Margaretta Page and Anne Fedoroff and Jane Rabbitt and Nicholas Butowski and Michael Prados and Chang, {Susan M.}",
year = "2009",
month = "2",
day = "1",
doi = "10.1215/15228517-2008-063",
language = "English (US)",
volume = "11",
pages = "59--68",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Quality of life in low-grade glioma patients receiving temozolomide

AU - Liu, Raymond

AU - Solheim, Karla

AU - Polley, Mei-Yin

AU - Lamborn, Kathleen R.

AU - Page, Margaretta

AU - Fedoroff, Anne

AU - Rabbitt, Jane

AU - Butowski, Nicholas

AU - Prados, Michael

AU - Chang, Susan M.

PY - 2009/2/1

Y1 - 2009/2/1

N2 - The purpose of this study was to describe the quality of life (QOL) of low-grade glioma (LGG) patients at baseline prior to chemotherapy and through 12 cycles of temozolomide (TMZ) chemotherapy. Patients with his- tologically confirmed LGG with only prior surgery were given TMZ for 12 cycles. QOL assessments by the Functional Assessment of Cancer Therapy-Brain (FACT-Br) were obtained at baseline prior to chemotherapy and at 2-month intervals while receiving TMZ. Patients with LGG at baseline prior to chemotherapy had higher reported social well-being scores (mean difference = 5.0; p < 0.01) but had lower reported emotional well-being scores (mean difference = 2.2; p &t 0.01) compared to a normal population. Compared to patients with left hemisphere tumors, patients with right hemisphere tumors reported higher physical well-being scores (p = 0.01): 44% could not drive, 26% did not feel independent, and 26% were afraid of having a seizure. Difficulty with work was noted in 24%. Mean change scores at each chemotherapy cycle compared to baseline for all QOL subscales showed either no significant change or were significantly positive (p < 0.01). Patients with LGG on TMZ at baseline prior to chemotherapy reported QOL comparable to a normal population with the exception of social and emotional well-being, and those with right hemisphere tumors reported higher physical well-being scores compared to those with left hemisphere tumors. While remaining on therapy, LGG patients were able to maintain their QOL in all realms. LGG patients' QOL may be further improved by addressing their emotional well-being and their loss of independence in terms of driving or working.

AB - The purpose of this study was to describe the quality of life (QOL) of low-grade glioma (LGG) patients at baseline prior to chemotherapy and through 12 cycles of temozolomide (TMZ) chemotherapy. Patients with his- tologically confirmed LGG with only prior surgery were given TMZ for 12 cycles. QOL assessments by the Functional Assessment of Cancer Therapy-Brain (FACT-Br) were obtained at baseline prior to chemotherapy and at 2-month intervals while receiving TMZ. Patients with LGG at baseline prior to chemotherapy had higher reported social well-being scores (mean difference = 5.0; p < 0.01) but had lower reported emotional well-being scores (mean difference = 2.2; p &t 0.01) compared to a normal population. Compared to patients with left hemisphere tumors, patients with right hemisphere tumors reported higher physical well-being scores (p = 0.01): 44% could not drive, 26% did not feel independent, and 26% were afraid of having a seizure. Difficulty with work was noted in 24%. Mean change scores at each chemotherapy cycle compared to baseline for all QOL subscales showed either no significant change or were significantly positive (p < 0.01). Patients with LGG on TMZ at baseline prior to chemotherapy reported QOL comparable to a normal population with the exception of social and emotional well-being, and those with right hemisphere tumors reported higher physical well-being scores compared to those with left hemisphere tumors. While remaining on therapy, LGG patients were able to maintain their QOL in all realms. LGG patients' QOL may be further improved by addressing their emotional well-being and their loss of independence in terms of driving or working.

KW - Brain tumor, chemotherapy

KW - Low-grade glioma

KW - Quality of life

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=61449249107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449249107&partnerID=8YFLogxK

U2 - 10.1215/15228517-2008-063

DO - 10.1215/15228517-2008-063

M3 - Article

C2 - 18713953

AN - SCOPUS:61449249107

VL - 11

SP - 59

EP - 68

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 1

ER -